Neuropeptide GPCRs in neuroendocrinology: The case of activity-dependent neuroprotective protein (ADNP)

Frontiers in Endocrinology

Volumn 3, Issue NOV, 2012, Pages

  Gozes, Illana ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874421732     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00134     Document Type: Article

References (43)

1. Abad, C., Tan, Y. V., Lopez, R., Nobuta, H., Dong, H., Phan, P., et al. (2010). Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U.S.A. 107, 19555-19560.
2. Ashur-Fabian, O., Giladi, E., Brenneman, D. E., and Gozes, I. (1997). Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides. J. Mol. Neurosci. 9, 211-222.
3. Bassan, M., Zamostiano, R., Davidson, A., Pinhasov, A., Giladi, E., Perl, O., et al. (1999). Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J. Neurochem. 72, 1283-1293.
4. Blondel, O., Collin, C., McCarran, W. J., Zhu, S., Zamostiano, R., Gozes, I., et al. (2000). A glia-derived signal regulating neuronal differentiation. J. Neurosci. 20, 8012-8020.
5. Bodner, M., Fridkin, M., and Gozes, I. (1985). Coding sequences for vasoactive intestinal peptide and PHM-27 peptide are located on two adjacent exons in the human genome. Proc. Natl. Acad. Sci. U.S.A. 82, 3548-3551.
6. Braitch, M., Kawabe, K., Nyirenda, M., Gilles, L. J., Robins, R. A., Gran, B., et al. (2009). Expression of activity-dependent neuroprotective protein in the immune system: possible functions and relevance to multiple sclerosis. Neuroimmunomodulation 17, 120-125.
7. Brenneman, D. E., and Gozes, I. (1996). A femtomolar-acting neuroprotective peptide. J. Clin. Invest. 97, 2299-2307.
8. Brenneman, D. E., Neale, E. A., Foster, G. A., d'Autremont, S. W., and Westbrook, G. L. (1987). Nonneuronal cells mediate neurotrophic action of vasoactive intestinal peptide. J. Cell Biol. 104, 1603-1610.
9. Card, J. P., Fitzpatrick-McElligott, S., Gozes, I., and Baldino, F. Jr. (1988). Localization of vasopressin-, vasoactive intestinal polypeptide-, peptide histi-dine isoleucine- and somatostatin-mRNA in rat suprachiasmatic nucleus. Cell Tissue Res. 252, 307-315.
10. Dresner, E., Agam, G., and Gozes, I. (2011). Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia. Eur. Neuropsychopharmacol. 21, 355-361.
11. Furman, S., Steingart, R. A., Mandel, S., Hauser, J. M., Brenneman, D. E., and Gozes, I. (2004). Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biol. 1, 193-199.
12. Giladi, E., Hill, J. M., Dresner, E., Stack, C. M., and Gozes, I. (2007). Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotec-tive protein (ADNP) expression in vivo. J. Mol. Neurosci. 33, 278-283.
13. Glowa, J. R., Panlilio, L. V., Brenneman, D. E., Gozes, I., Fridkin, M., and Hill, J. M. (1992). Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Res. 570, 49-53.
14. Gold, M., Lorenzl, S., Stewart, A. J., Morimoto, B. H., Williams, D. R., and Gozes, I. (2012). Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr. Dis. Treat 8, 85-93.
15. Gourlet, P., Rathe, J., De Neef, P., Cnudde, J., Vandermeers-Piret, M. C., Waelbroeck, M., et al. (1998). Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors. Eur. J. Pharmacol. 354, 105-111.
16. Gozes, I. (2007). Activity-dependent neuroprotective protein: from gene to drug candidate. Pharmacol. Ther. 114, 146-154.
17. Gozes, I. (2008). VIP, from gene to behavior and back: summarizing my 25 years of research. J. Mol. Neurosci. 36, 115-124.
18. Gozes, I., Glowa, J., Brenneman, D. E., McCune, S. K., Lee, E., and Westphal, H. (1993). Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene. J. Mol. Neurosci. 4, 185-193.
19. Gozes, I., Lilling, G., Glazer, R., Ticher, A., Ashkenazi, I. E., Davidson, A., et al. (1995). Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J. Pharmacol. Exp. Ther. 273, 161-167.
20. Gozes, I., McCune, S. K., Jacobson, L., Warren, D., Moody, T. W., Fridkin, M., et al. (1991). An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J. Pharmacol. Exp. Ther. 257, 959-966.
21. Gozes, I., Perl, O., Giladi, E., Davidson, A., Ashur-Fabian, O., Rubinraut, S., et al. (1999). Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design. Proc. Natl. Acad. Sci. U.S.A. 96, 4143-4148.
22. Gozes, I., Shani, Y., and Rostene, W. H. (1987). Developmental expression of the VIP-gene in brain and intestine. Brain Res. 388, 137-148.
23. Gressens, P., Hill, J. M., Gozes, I., Fridkin, M., and Brenneman, D. E. (1993). Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature 362, 155-158.
24. Gressens, P., Hill, J. M., Paindaveine, B., Gozes, I., Fridkin, M., and Brenneman, D. E. (1994). Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. J. Clin. Invest. 94, 2020-2027.
25. Harmar, A. J., Fahrenkrug, J., Gozes, I., Laburthe, M., May, V., Pisegna, J. R., et al. (2012). Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br. J. Pharmacol. 166, 4-17.
26. Harmar, A. J., Marston, H. M., Shen, S., Spratt, C., West, K. M., Sheward, W. J., et al. (2002). The VPAC(2) receptor is essential for circadian function in the mouse suprachiasmatic nuclei. Cell 109, 497-508.
27. Hill, J. M., Hauser, J. M., Sheppard, L. M., Abebe, D., Spivak-Pohis, I., Kushnir, M., et al. (2007). Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry. J. Mol. Neurosci. 31, 183-200.
28. Hill, J. M., Mervis, R. F., Politi, J., McCune, S. K., Gozes, I., Fridkin, M., et al. (1994). Blockade of VIP during neonatal development induces neu-ronal damage and increases VIP and VIP receptors in brain. Ann. N.Y. Acad. Sci. 739, 211-225.
29. Kushnir, M., Dresner, E., Mandel, S., and Gozes, I. (2008). Silencing of the ADNP-family member, ADNP2, results in changes in cellular viability under oxidative stress. J. Neurochem. 105, 537-545.
30. Loh, D. H., Dragich, J. M., Kudo, T., Schroeder, A. M., Nakamura, T. J., Waschek, J. A., et al. (2011). Effects of vasoactive intestinal peptide genotype on circadian gene expression in the suprachiasmatic nucleus and peripheral organs. J. Biol. Rhythms 26, 200-209.
31. Mandel, S., Rechavi, G., and Gozes, I. (2007). Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev. Biol. 303, 814-824.
32. Mandel, S., Spivak-Pohis, I., and Gozes, I. (2008). ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance. J. Mol. Neurosci. 35, 127-141.
33. Moody, T. W., Jensen, R. T., Fridkin, M., and Gozes, I. (2002). (N-stearyl, norleucine17) VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist. J. Mol. Neurosci. 18, 29-35.
34. Nakamachi, T., Li, M., Shioda, S., and Arimura, A. (2006). Signaling involved in pituitary adenylate cyclase-activating polypeptide-stimulated ADNP expression. Peptides 27, 1859-1864.
35. Nakamachi, T., Ohtaki, H., Yofu, S., Dohi, K., Watanabe, J., Hayashi, D., et al. (2008). Pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor (PAC1R) co-localizes with activity-dependent neuroprotective protein (ADNP) in the mouse brains. Regul. Pept. 145, 88-95.
36. Pascual, M., and Guerri, C. (2007). The pep-tide NAP promotes neuronal growth and differentiation through extracellular signal-regulated protein kinase and Akt pathways, and protects neurons co-cultured with astro-cytes damaged by ethanol. J. Neurochem. 103, 557-568.
37. Pilzer, I., and Gozes, I. (2006). VIP provides cellular protection through a specific splice variant of the PACAP receptor: a new neuroprotection target. Peptides 27, 2867-2876.
38. Pinhasov, A., Mandel, S., Torchinsky, A., Giladi, E., Pittel, Z., Goldsweig, A. M., et al. (2003). Activity-dependent neuroprotec-tive protein: a novel gene essential for brain formation. Brain Res. Dev. Brain Res. 144, 83-90.
39. Sigalov, E., Fridkin, M., Brenneman, D. E., and Gozes, I. (2000). VIP-related protection against lodoacetate toxicity in pheochro-mocytoma (PC12) cells: a model for ischemic/hypoxic injury. J. Mol. Neurosci. 15, 147-154.
40. Vulih-Shultzman, I., Pinhasov, A., Mandel, S., Grigoriadis, N., Touloumi, O., Pittel, Z., et al. (2007). Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphos-phorylation and enhances learning in a novel transgenic mouse model. J. Pharmacol. Exp. Ther. 323, 438-449.
41. Zamostiano, R., Pinhasov, A., Gelber, E., Steingart, R. A., Seroussi, E., Giladi, E., et al. (2001). Cloning and characterization of the human activity-dependent neuroprotective protein. J. Biol. Chem. 276, 708-714.
42. Zupan, V., Hill, J. M., Brenneman, D. E., Gozes, I., Fridkin, M., Robberecht, P., et al. (1998). Involvement of pituitary adenylate cyclase-activating polypeptide II vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis. J. Neurochem. 70, 2165-2173.
43. Zusev, M., and Gozes, I. (2004). Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regul. Pept. 123, 33-41.